7 2 7 a r t i c l e s LEN, a synthetic glutamic acid derivative, is approved for the treatment of hematological malignancies, including MDS and multiple myeloma 1 . Myelodysplastic syndromes are hematopoietic stem cell (HSC) disorders that are characterized by ineffective hematopoiesis, peripheral cytopenias, and a propensity for progression to AML. LEN is approved for the treatment of lower-risk del(5q) MDS, and it provides durable hematologic and cytogenetic responses in the majority of patients 2 . LEN is also effective in a subset of individuals with non-del(5q) MDS, but only for 26% of the patients 3 . LEN has diverse biological effects-including the suppression of inflammatory cytokines, the inhibition of MDM2 proto-oncoprotein (MDM2) activity via serine/threonine protein phosphatase 2A (PP2A) and cell division cycle 25C (CDC25C), and the stimulation of T lymphocytes 4,5 . More recently, LEN has been shown to bind directly to cereblon (CRBN), a substrate receptor of the CRL4 CRBN E3 ligase complex 6 , which results in the ubiquitination and degradation of select protein targets. LEN treatment promotes CRBN-dependent degradation of IKZF1 and IKZF3, as well as degradation of casein kinase I isoform alpha (CSNK1A1; also known as CK1-α), which are key factors in hematologic diseases [7] [8] [9] . Despite the identification of these direct CRL4 CRBN targets, the mechanistic basis for the therapeutic effects of LEN in MDS is not fully understood. Insight into LEN's mechanism of action may improve our understanding of clinical response and inform rational combinatorial therapeutic approaches.
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RESULTS
A genome-wide RNA interference screen identifies determinants of LEN sensitivity in MDS Although very few cellular models of MDS exist, we have previously extensively characterized a LEN-sensitive cell line, MDSL, which was derived from a patient with lower-risk MDS 10, 11 . MDSL cells show incomplete differentiation and propagate in vitro as a heterogeneous mixture of functionally distinct immature CD34 + hematopoietic stem and progenitor cells and mature CD34 -myeloid cells (Supplementary Fig. 1a ). Treatment with LEN suppressed colony formation of CD34 + MDSL cells in methylcellulose ( Supplementary  Fig. 1b) , induced apoptosis (annexin V + cells) of MDSL cells specifically within the CD34 -subpopulation (Supplementary Fig. 1c) , and impaired total cell growth in liquid culture 12 ( Supplementary  Fig. 1d ). Thus, LEN treatment has pleiotropic effects on MDSL cell function and viability by targeting both the CD34 + and CD34 -subpopulations. As expected, the effects of LEN were mediated by CRBN, as knockdown of CRBN expression in MDSL cells completely abrogated LEN-mediated colony inhibition ( Supplementary Fig. 1e,f) . Overall, MDSL cells represent a tractable in vitro model to study the pleiotropic effects of LEN on MDS cell viability, proliferation, and clonogenicity.
To identify genes and/or regulatory networks that are critical for a LEN-mediated response, we performed a genome-wide RNA interference (RNAi)-based loss-of-function genetic screen using LEN-treated MDSL cells (Fig. 1a) . The library of 200,000 lentiviral-packaged shRNAs, which targets 47,400 human transcripts listed in the National Center for Biotechnology Information (NCBI) RefSeq database (3-5 shRNAs per transcript, including mRNAs and expressed sequence tags (ESTs)), was constructed in a feline immunodeficiency virus (FIV)-based vector (pSIF-H1-copGFP) that co-expresses green fluorescent protein (GFP) (referred to as the SBI library). We confirmed that lentiviral transduction of MDSL cells with an empty vector (pSIF-H1-copGFP) did not modify the response of the cells to LEN treatment (Supplementary Fig. 2a,b) .
The sequences of the shRNA templates corresponded to probes on the Affymetrix U133 Plus 2.0 GeneChip Array, allowing for postscreening identification of shRNAs by microarray analysis. MDSL cells were transduced with the lentiviral shRNA library and sorted for GFP-expressing cells. These cells were then treated with 10 µM LEN (or DMSO) for 7 d (Fig. 1a and Supplementary Fig. 2b ).
The design of the screen permitted for enrichment of shRNAs that impair LEN-induced cytotoxicity. A total of 470 shRNAs were differentially enriched after LEN treatment (Supplementary Table 1) , of which 256 were positively enriched (Fig. 1b) . By using a scoring criterion of ≥1.5-fold enrichment in two replicate screens (false discovery rate (FDR)-adjusted P < 0.05) by at least two independent shRNAs, we compiled a narrowed list of 24 enriched shRNAs that are presumed to target genes involved in mediating sensitivity to LEN (Fig. 1c) . To assess possible interactions between these candidate LEN-sensitivity genes, pathway analysis was performed using NetWalker analysis 13 . One of the molecular networks identified was the tumor protein 53 (TP53; encoding p53) pathway (data not shown), which has previously been implicated in LEN resistance and relapse in patients with MDS 14 . Although it did not fulfill our selection GPR68  EPM2A  CHGB  RCAN1  NOL6  DSG3  SNX4  RRP1B  IMMT  NPC2  ITGA4  EIF2S2  PEX11A  THPO  SAA1  RORB  SAT1  VCAM1  CIP29  ADRB1  ZNF79  PGLYRP1  RIC8B , and GPR68 and IKZF1 protein expression (right), in MDSL cells that were treated with DMSO or 10 µM LEN (n = 3). GAPDH was used as a loading control. (g) GPR68 mRNA expression in primary CD34 + (n = 4 per group) and primary MDS BM HSPCs (MDS-1) (n = 3 per group; error bars were derived from technical replicates) that were treated with DMSO or 10 µM LEN.
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criteria, an shRNA targeting CRBN was also enriched in cells that were treated with LEN, which is consistent with previous reports and which established the validity of the RNAi screen ( Supplementary  Fig. 3a ) 9 . Moreover, on the basis of knockdown experiments in MDSL cells with shRNAs from a different library (the RNAi Consortium; TRC), four of eight 'hits' were confirmed to reduce sensitivity to LEN ( Supplementary Figs. 1f and 3b) .
IKZF1 regulates GPR68 expression in MDS
Following LEN treatment, IKZF1 is degraded by the CRL4 CRBN E3 ligase complex 8, 9, 15 . Because IKZF1 is a direct substrate of CRBN and can function as a transcriptional repressor or activator 16 , the list of hits was narrowed by examining the promoters of the genes that were targeted by the enriched shRNAs for occupancy with IKZF1 ( Supplementary Fig. 4) . Examination of promoter regions-by use of the Encyclopedia of DNA Elements (ENCODE) functional genomics data from a normal lymphoblastoid cell line 17 -revealed three genes (interferon regulatory factor 9 (IRF9), serum amyloid A1 (SAA1), and G-protein-coupled receptor 68 (GPR68) that contained binding peaks for IKZF1, as measured by chromatin immunoprecipitation sequencing (ChiP-seq) ( Fig. 1d and Supplementary Fig. 4 ). Of the LEN-sensitivity genes identified in the screen, GPR68 emerged as the leading candidate because: (i) shRNAs targeting GPR68, which were represented by three independent RNAi sequences, showed the highest level of enrichment (Fig. 1c); (ii) the GPR68 promoter shows robust IKZF1 promoter occupancy by ChiP-seq (Fig. 1e) ; and (iii) GPR68 mRNA and GPR68 protein expression increased in MDSL cells, primary MDS hematopoietic stem-progenitor cells (HSPCs), and normal CD34 + cells, following LEN treatment, which coincided with IKZF1 protein degradation (Fig. 1f,g ). To confirm IKZF1-mediated regulation of GPR68, IKZF1 was either knocked down in MDSL cells using shRNAs or was overexpressed. Consistent with its role as a transcriptional repressor, reduced IKZF1 expression de-repressed GPR68 mRNA expression by ~4-fold (Fig. 1h) , whereas overexpression of a degradation-resistant IKZF1 mutant (IKZF1 Q146H ) but not of wild-type (WT) IKZF1 maintained GPR68 repression after LEN treatment (Fig. 1i) . Moreover, the LEN-mediated increase in GPR68 expression is CRBN dependent, as knockdown of CRBN prevented LEN-induced GPR68 expression ( Fig. 1j and Supplementary Fig. 1e ). Taken together, these results demonstrate that GPR68 is a LEN-and CRBN-responsive gene that is regulated by IKZF1 in MDS cells.
GPR68 is a determinant of LEN sensitivity in MDS GPR68, also known as OGR1, belongs to a family of proton-sensing G-protein-coupled receptors 18 . After extracellular acidosis, GPR68 is activated and couples to G q/11 , resulting in signaling to the phospholipase-C-calcium (Ca 2+ ) pathway (Fig. 2a) 18, 19 . We validated the requirement of GPR68 for LEN sensitivity by using two additional independent shRNAs. Consistent with the results of the RNAi screen, knockdown of GPR68 reversed the inhibitory effects of LEN on MDSL colony formation in methylcellulose ( Fig. 2b-d ; P < 0.05) and on cell viability (Supplementary Fig. 5a ; P < 0.05). Knockdown of GPR68 did not affect CRBN expression or CRBN substrate degradation ( Supplementary Fig. 5b,c) .
To determine the requirement of GPR68 for LEN sensitivity in vivo, MDSL cells (1 × 10 6 ) expressing either a control shRNA (shCtl) or a GPR68-specific shRNA (shGPR68) were engrafted intravenously (i.v.) into immunocompromised NOD-SCID-IL2R-γ (NSG) mice (Fig. 2e) . Ten days after engraftment, LEN (25 mg/ per kg body weight (mg/kg)) or vehicle (DMSO) was administered by intraperitoneal (i.p.) injection for 4 weeks, as previously described 20 , after which the level of MDSL cell engraftment in the bone marrow (BM) (double-positive human CD45 + GFP + cells) was determined. In mice that were transplanted with control MDSL cells (expressing shCtl), BM engraftment was 60% less after LEN treatment as compared to that with DMSO treatment (0.41 ± 0.19; P = 0.1) (Fig. 2f) . In contrast, mice that were transplanted with shGPR68-expressing MDSL cells were less sensitive to LEN treatment, as BM engraftment was comparable in mice treated with LEN or DMSO (0.80 ± 0.27, P = 0.4) (Fig. 2f) . These data indicate that GPR68 expression is necessary for LEN sensitivity of MDS cells in vitro and in vivo. GPR68 can be activated with a G protein receptor agonist (Ncyclopropyl-5-(thiophen-2-yl)-isoxaole-3-carboxamide (Lsx)), independently of extracellular pH levels (Fig. 2a) 21 . Treatment of MDSL cells with 10 µM Lsx inhibited colony formation and induced apoptosis to a similar extent as did LEN treatment ( Fig. 2g  and Supplementary Fig. 6a ). The effect of Lsx on MDSL requires GPR68, as knockdown of GPR68 reversed the inhibitory effects of Lsx (Fig. 2g) . In addition, LEN and Lsx cooperatively inhibited MDS cell function. Co-treatment of MDSL cells or primary MDS BM cells with LEN (10 µM) and Lsx (10 µM) resulted in further reductions in colony formation (Fig. 2h) and cell viability (Supplementary Fig. 6a,b) , as compared to those with individual treatments. To establish whether GPR68 overexpression is sufficient to affect MDS cell function and LEN sensitivity, MDSL cells were transduced with a retroviral vector (MSCV-IRES-GFP; hereafter referred to as MIG) expressing GPR68 (MIG-GPR68) and then treated with LEN (10 µM) in methylcellulose (Supplementary Fig. 6c ). GPR68 overexpression significantly suppressed MDSL colony formation, which was further suppressed in the presence of LEN ( Fig. 2i ; P < 0.05), suggesting that activation or overexpression of GPR68 can enhance LEN sensitivity. LEN sensitivity is regulated by GPR68-mediated intracellular calcium flux A cellular consequence of GPR68 activation is an increase in cytoplasmic calcium levels 18, 22 . We therefore investigated whether intracellular calcium levels affected LEN sensitivity by using calcium chelators and inducers (Figs. 2a and 3a-d) . Treatment with EGTA or BAPTA, which block extracellular and intracellular calcium, respectively, restored colony formation ( Fig. 3a ; P < 0.05) and cell survival ( Fig. 3b,d ; P < 0.05) of LEN-treated MDSL cells. Ionomycin treatment, which elevates cytosolic calcium levels, further reduced MDSL colony formation and survival when administered together with LEN (Fig. 3a,c,d ). These findings reveal the importance of cytosolic calcium to LEN function. Next we examined whether LEN directly affects cytosolic calcium concentrations. Using a fluorescence dye that detects free cytosolic calcium (Fluo-4), we examined two mechanisms of calcium induction in MDSL cells-acutely modulated calcium flux and progressive calcium accumulation (Fig. 3e, left) . Whereas treatment with ionomycin rapidly induced calcium influx within seconds, cytosolic calcium levels did not increase immediately after addition of LEN (Fig. 3e, top right) . Treatment of MDSL cells with LEN for ≥2 d, however, resulted in elevated cytosolic calcium levels (Fig. 3e (bottom  right) ,f) and further increased ionomycin-induced calcium levels (Fig. 3e, bottom right) . To evaluate whether LEN affects calcium levels in vivo, we generated MDSL xenografts in NSG mice followed by injection of DMSO or LEN, as in Figure 2e . Consistent with the in vitro data, in vivo administration of LEN increased intracellular calcium levels in MDSL cells (Fig. 3g) . In addition, pomalidomide (POM) treatment also elevated calcium levels in MDSL cells in vitro, indicating that the observed effect of LEN on calcium extends to other immunomodulating drugs (Fig. 3g) . Knockdown of GPR68 or CRBN prevented increases in calcium levels in LEN-treated MDSL cells (Fig. 3h) , indicating that LEN treatment gradually increases cytosolic calcium concentrations through CRBN and GPR68 signaling. To examine the potential correlation between LEN-mediated calcium flux and cell function, a panel of MDS and AML cell lines was evaluated for changes in cytosolic calcium, progenitor function in methylcellulose, cell viability, and CRBN substrate degradation. MDSL, TF1, and MOLM13 cells were the most sensitive to LEN treatment, as indicated by reduced colony formation and viability ( Supplementary  Fig. 7a,b) . In contrast, HL60, Kasumi, and THP1 cells were resistant to LEN treatment, whereas KG-1α and F36P cells showed an intermediate response. In the cell lines tested, we did not observe a correlation between LEN sensitivity and basal cytosolic calcium or GPR68 mRNA levels, or between LEN sensitivity and LEN-induced GPR68 expression (Supplementary Fig. 7c-f) . However, the LEN-induced increases in calcium levels were observed in the LEN-sensitive but not the LEN-resistant cell lines (Fig. 3i) . LEN sensitivity of the cell lines was not simply CRBN dependent, as LEN treatment resulted in CRBN substrate degradation in nearly all of the cell lines ( Supplementary  Fig. 7g ). POM treatment was also effective in suppressing viability and function of MDS and AML cells (Supplementary Fig. 8a) , and its inhibitory effects also correlated with effects on calcium flux in the cell lines tested (Fig. 3i and Supplementary Fig. 8b ). Primary del(5q) MDS cells are known to be more sensitive to LEN as compared to normal BM cells 2 . Although basal calcium levels were variable among primary BM samples from three individuals with del(5q) MDS and CD34 + cell samples from two normal, healthy donors, only the MDS samples showed an increase in cytosolic calcium levels after 2 d of LEN treatment in vitro (Fig. 3j) . Together, these data indicate that LENmediated cytotoxicity in MDS and AML cell lines and in primary cells from individuals with MDS requires intracellular calcium flux.
Calcium-dependent calpain activity is required for LEN sensitivity
Calcium is an important second messenger that has been implicated in cell fate decisions 23 . Therefore, we next attempted to identify the calcium-dependent molecular mechanism that mediates the cytotoxic effects of LEN. We screened a series of pharmacological inhibitors for their efficacy in reversing LEN-mediated cytotoxicity of MDSL cells and selected five commercially available small molecules that represented inhibitors of major cell death pathways-including inhibitors of apoptosis-inducing factor (AIF), cathepsins, caspases, and calpains. Among the inhibitors, treatment with only the calpain inhibitor (PD160505) prevented LEN-and POM-induced apoptosis of MDSL cells (Fig. 4a-c) , implicating calpains in immunomodulatory drug (IMiD)-mediated cell death. Calpains are a family of calcium-dependent cysteine proteases, of which calpain 1 (CAPN1) and CAPN2 are the most abundant 24 . Because elevated calcium levels can stimulate calpain protease activity 25 , we next determined whether LEN regulates calpain activation by using a luminescence assay for calpain substrate cleavage by lysates of LEN-treated cells. LEN treatment of MDSL cells for 4 d resulted in cleavage of the calpain substrate (P < 0.05) to a similar extent as that observed with ionomycin treatment (positive control) (Fig. 4d) . In contrast, treatment of the LEN-resistant cell line HL60 with LEN did not result in cleavage of the calpain substrate (Fig. 4d) , suggesting that LEN sensitivity correlates with calpain activation. Moreover, primary MDS BM cells also showed increased calpain substrate cleavage following treatment of the cells with LEN ( Fig. 4e ; P < 0.05). LEN-induced cleavage of calpain substrates was inhibited in MDSL cells after knockdown of GPR68 or CRBN (Fig. 4f) . Collectively, these observations add credence to a model in which sensitivity of MDS and AML cells to LEN correlates with calcium-induced calpain activation.
Reduced CAST and increased CAPN1 confer sensitivity of MDS to LEN To further explore the mechanism of LEN sensitivity, we performed global proteomic analyses of LEN-treated MDSL cells. A pathway analysis of differentially expressed proteins after LEN treatment revealed enrichment of mu-calpain (calpain 1) and m-calpain (calpain 2) pathways, but without reaching statistical significance (data not shown). Assessment of individual proteins from the calpain pathway signatures showed that the levels of both CAPN1 and its small subunit 1 (CAPNS1) increased ~2-fold in a time-dependent manner in LEN-treated MDSL cells (Fig. 5a) . To ascertain whether the increase in CAPN1 occurs in additional LEN-sensitive cell lines, we examined CAPN1 protein expression after LEN treatment of KG-1α and F36P cells. Consistent with the mass spectrometry findings for MDSL cells, LEN induced a ~2-fold increase in CAPN1 protein levels after a 96-h treatment in KG-1α and F36P cells (Fig. 5b) . In contrast, treatment of the LEN-resistant HL60, THP1 and Kasumi1 cell lines with LEN did not result in increased CAPN1 levels (Fig. 5b) . Increased CAPN1 protein expression was also observed after POM treatment of sensitive but not resistant AML cells (Supplementary Fig. 8c ). Knockdown of IKZF1 or GPR68, or overexpression of GPR68, in untreated MDSL cells did not affect CAPN1 protein expression, indicating that the regulation of CAPN1 protein expression is probably independent of IKZF1 and GPR68 (Supplementary Fig. 9 ).
To determine whether calpains are necessary for mediating LENinduced cytotoxicity, CAPN1 and CAPN2 expression were knocked down in MDSL cells (Supplementary Fig. 10a,b) . Although basal colony formation was impaired for CAPN1-or CAPN2-depleted cells, treatment with LEN did not inhibit colony formation for CAPN1-depleted MDSL cells (Fig. 5c) (Fig. 3i) as either Ca 2+ responsive or Ca 2+ nonresponsive. (i) Colony formation (bottom) by MDSL cells that were transduced with an empty lentiviral expression vector (Vec) or one that expresses CAST, as determined by immunoblot analysis (top), and that were treated with DMSO or 10 µM LEN (n = 3 per group from independent experiments). (j) Overview of the proposed mechanism by which LEN, acting through CRBN, induces IKZF1 degradation and GRP68 upregulation, leading to increased intracellular calcium levels and calpain activation. Prior to treatment (no treatment), MDS cells express IKZF1, which suppresses GPR68 expression and intracellular Ca 2+ levels. In LEN-sensitive cells, LEN treatment results in IKZF1 degradation (via CRBN), which leads to de-repression of GPR68 expression, increased calcium levels, and activation of CAPN1. In LEN-resistant cells, various connections in the CRBN-IKZF1-GPR68-Ca 2+ -CAPN1 network could be disrupted and/or inhibited, permitting MDS cell expansion. Throughout, error bars represent mean ± s.e.m. *P < 0.05 by Student's t-test. npg a r t i c l e s nature medicine VOLUME 22 | NUMBER 7 | JULY 2016 (Supplementary Fig. 10c) . In contrast, knockdown of CAPN2 did not affect the ability of LEN to inhibit MDSL colony formation (Fig. 5d) . These data implicate CAPN1 as a mediator of LEN-induced cytotoxicity. Notably, for one LEN-sensitive cell line (TF1 cells), increased calpain activity or CAPN1 expression was not observed following LEN treatment, suggesting that alternative mechanisms of LEN action exist (Supplementary Fig. 11 ). Given that our findings implicate calcium-dependent calpain activation in LEN-induced cell death, we speculated that impaired regulation of calcium signaling or calpain activation would affect LEN sensitivity in patients with del(5q) MDS. To explore this connection, we searched for genes that encode known calcium and/or calpain regulators and that are located on chromosome 5q. Notably, the gene encoding calpastatin (CAST), a physiological inhibitor of CAPN1, is located at 5q15 (ref. 26) . On the basis of publically available gene expression data 27 , we found CAST mRNA expression to be significantly reduced in del(5q) MDS CD34 + cells as compared to CD34 + MDS cells with a normal 5q copy number (dip(5q) MDS cells) (P < 0.05; Fig. 5e ). Moreover, as compared to non-responders, patients with MDS who responded to LEN treatment expressed CAST in BM mononuclear cells (MNCs) at lower levels, independently of chromosome 5q deletion status (n ≥ 6 per group; P = 0.01; two-tailed t-test; Fig. 5f ). To confirm these observations, we examined CAST expression in an independent cohort of del(5q) MDS samples from subjects who either responded to or were refractory to LEN treatment. Individuals with MDS who responded to LEN treatment expressed CAST in BM MNCs at lower levels than nonresponders or control BM cells ( Fig. 5g ; P = 0.01). Collectively, these findings suggest that haploid expression of CAST may be necessary to achieve sufficient calpain activation in LEN-treated cells.
To test the hypothesis that reduced CAST expression sensitizes cells to LEN, we knocked down CAST in AML cell lines that are either responsive (KG-1α and F36P) or unresponsive (Kasumi and THP1) to calcium induction by LEN. KG-1α and F36P cells were selected as they show increased intracellular calcium and calpain expression after LEN treatment but remain less sensitive to the cytotoxic effects of LEN (Supplementary Table 2 ). In contrast, Kasumi and THP1 cells did not show increased intracellular calcium levels or increased calpain expression after LEN treatment, and therefore they should not be sensitized to LEN following CAST knockdown. After knockdown of CAST, the cells were plated in methylcellulose with 10 µM LEN. As observed for CAPN1-depleted cells, knockdown of CAST affected basal colony formation. Nevertheless, after the knockdown of CAST, KG-1α and F36P cells acquired increased sensitivity to LEN, as relative colony formation was reduced by >50% (P < 0.05; Fig. 5h ). In contrast, knockdown of CAST in Kasumi and THP1 cells did not cooperate with LEN to suppress colony formation (Fig. 5h) . Finally, re-expression of CAST in LEN-sensitive MDSL cells conferred resistance to LEN, as indicated by restored colony formation (Fig. 5i) . In conclusion, these findings support a model in which haploid expression of CAST sensitizes 'primed' cells to LEN-induced calpain activation in del(5q) MDS (Fig. 5j) .
DISCUSSION
By taking a nonbiased genome-wide screening approach, our study identified a cellular mechanism of LEN action in MDS and AML that relies on a calcium-calpain-dependent pathway. LEN treatment increased cytosolic calcium levels in MDS and AML cells to a greater extent than in normal HSPCs. Elevated cytosolic calcium levels was not observed in LEN-resistant MDS or AML cell lines, suggesting that calcium signaling is associated with LEN-induced cell death.
Elevated calcium levels resulted in activation of calpains, a family of calcium-dependent proteases responsible for initiating apoptosis, providing a mechanistic explanation for LEN-induced cytotoxicity. A high-throughput proteomic mass spectrometry approach identified increased CAPN1 protein abundance after LEN treatment as the strongest effect in the calpain protein signature. Collectively, these observations reveal that LEN concurrently induces cytosolic calcium and CAPN1 protein expression, maximizing the sensitivity of MDS cells to LEN-induced apoptosis. Furthermore, we propose that haploid expression of the gene encoding the physiological inhibitor of CAPN1, CAST (5q15), permits full activation of CAPN1 in LEN-treated del(5q) MDS cells (Fig. 5j) . Our in vitro studies also revealed that a LEN-sensitive cell line (TF1 cells) showed an increase in cytosolic calcium levels but not in calpain activation, and that a cell line that showed only a minor cytotoxic effect of LEN treatment (F36P cells) had increased CAPN1 expression. Nevertheless, induced CAPN1 expression and cytosolic calcium flux were closely tied to LEN responsiveness. Thus, we postulate that baseline CAST and/or induced CAPN1 expression, in addition to calcium flux, may predict LEN responsiveness in individuals with MDS or AML.
LEN induces ubiquitination and degradation of IKZF1, IKZF3, and CK1-α by co-opting CRBN E3 ligase activity. IKZF1 and IKZF3 are transcription factors that are highly expressed in myeloid and lymphoid malignancies, and their degradation by LEN has been linked to T cell stimulation and cytotoxicity in multiple myeloma cells 28 . Here we show that LEN treatment leads to the death of MDS and AML cells, by linking degradation of IKZF1 to de-repression of GPR68 and subsequent calcium-calpain activation. In addition, CK1-α is encoded by a gene located in the deleted region for del(5q) MDS, and its haploinsufficient expression sensitizes cells to LEN treatment, providing a mechanistic explanation for the therapeutic window in patients with del(5q) MDS 8 . Degradation of CK1-α results in the stabilization of p53 and apoptosis of hematopoietic cells 29 , and it is well established that TP53 mutations confer resistance to LEN treatment in individuals with MDS 30 . Relevant to our findings, we found that p53 and calcium homeostasis are interdependent events, such that mutations in TP53 may also affect calcium signaling in MDS cells 31, 32 . Collectively, these observations suggest that degradation of IKZF1 and subsequent de-repression of GPR68, as well as degradation of CK1-α, are cooperative mechanisms mediating the effects of LEN in MDS and AML cells. Given the complexity of IKZF1-, IKZF3-, and CK1-α-regulated networks and their potentially distinct effects on myeloid biology, a comprehensive assessment of the effects of LEN-mediated degradation of these proteins, both individually and in combination, in del(5q) and normal-karyotype MDS is warranted.
A characteristic of LEN therapy is the selective suppression of MDSpropagating cells in parallel with the activation of T cells 5, 12 . The finding that LEN treatment leads to an elevation of intracellular calcium levels may provide a hint to explain this paradox. Our findings suggest that MDS and AML cells do not tolerate such an increase in intracellular calcium and undergo calpain-mediated apoptosis (Fig. 5j) . In stark contrast, high intracellular calcium levels in T cells leads to their activation via calcium-dependent signaling through the transcription factor NFAT 33 . This discrepancy in calcium tolerance between HSPCs and T cells may explain the differential response to LEN therapy. In summary, our findings describe a new cellular mechanism of LEN action through an IKZF1-and calcium-calpain-dependent pathway in del(5q) and non-del(5q) MDS and AML, which may improve our understanding of clinical responses and inform rational combinatorial therapeutic approaches. npg a r t i c l e s
ONLINE METHODS
shRNA library screen and data analysis. The loss-of-function screen was performed with GeneNet Lentiviral shRNA Libraries (System Biosciences; S12XXB-1) and analyzed by GeneNet Library Data Analysis Software (System Biosciences), according to the manufacturer's instructions. Briefly, vesicular stomatitis virus (VSV)-G (envelope glycoprotein)-pseudotyped lentiviral particles that target ~47,000 transcripts in the human genome according to the NCBI RefSeq database (GRCh38.p6) were transduced into 2 × 10 6 MDSL cells with a multiplicity of infection (MOI) of 0.5-1.0. Within this range, each cell that has successfully been transduced is expected to contain only one copy of a given shRNA construct. 3 d after transduction, GFP + transduced MDSL cells were purified for drug selection by using DMSO or 10 µM LEN treatment for 7 d. 5 × 10 6 viable MDSL cells were then isolated for RNA extraction. After two rounds of PCR, the amplified cDNA, corresponding to the unique shRNA hairpins, were labeled with biotin. After removing the sense strands, the biotin-labeled antisense strands were used as hybridization targets for Human Genome U133 Plus 2.0 GeneChip arrays (Affymetrix; #900470). GeneNet Library Data Analysis Software (System Biosciences) was used to generate expression values for individual shRNAs by comparing the background-corrected and normalized signal values for each shRNA in LEN-treated and control samples. The list of enriched shRNAs was calculated based on the absolute mean difference of expression values of shRNAs in LEN-versus control-treated replicate samples. Only shRNAs with >1.5-fold enrichment were further considered. P values were calculated based on the biological replicates of individual shRNA clones using the Student's t-test. To further narrow the list of hits for adjusted P values, a false discovery rate (FDR) correction was applied.
Primary samples and CD34 + cells. MDS MNCs from bone marrow aspirates were obtained at diagnosis as part of a multicenter phase 2 trial based in Italy. Diagnoses were performed at the University of Milan and informed consent was obtained. Human CD34 + umbilical cord blood (UCB) and normal BM MNC control samples were obtained from the Translational Research Development Support Laboratory of Cincinnati Children's Hospital under an approved Institutional Review Board protocol. Samples from both male and female subjects were analyzed. For RT-qPCR analysis, RNA was extracted from del(5q) MDS and age-matched healthy control BM MNCs. For measurement of intracellular calcium levels and calpain activity, MDS MNCs were cultured in StemSpan Serum-Free Expansion Medium (SFEM; Stemcell Technologies) supplemented with recombinant human stem cell factor (rhSCF; 02830, StemCell Technologies), human Flt3 ligand (rhFL; 02840, StemCell Technologies), human thrombopoietin (rhTPO; 02522, PeproTech), human interleukin (IL)-6 (rhIL-6; 02606, StemCell Technologies), and human recombinant IL-3 (rhIL-3; 02603, StemCell Technologies) at 10 ng/ml each. Human CD34 + UCB cells were maintained in StemSpan SFEM supplemented with 10 ng/ml of rhSCF, rhFL, rhTPO, rhIL-3, and rhIL-6.
Cell lines. HL60, THP1, Kasumi-1, KG-1α, and TF1 cells were purchased from the American Type Culture Collection. MOLM13 cells were purchased from AddexBio. F36P cells were purchased from Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ). The MDSL cell line was previously described 10 . Cell lines were cultured in RPMI 1640 medium with 10% FBS and 1% penicillin-streptomycin. KG-1α cells were cultured in 20% FBS. MDSL and TF1 cell lines were supplemented with 10 ng/ml rhIL-3. F36P cells were cultured with 10 ng/ml human recombinant granulocyte-macrophage colony-stimulating factor (rhGM-CSF; 300-03, PeproTech). All cell lines were confirmed by fingerprinting analysis and were found to be negative for mycoplasma.
Colony-forming assay. Based on a time-course analysis of LEN-treated cells in methylcellulose, the optimum time to assess colony formation was determined to be between days 7 and 14, before colony formation reached saturation. MDS or AML cells were plated in methylcellulose (4434; Stemcell Technologies) in the presence of DMSO or 10 µM LEN, and they were evaluated for colony formation after ~10 d. MDSL cells were plated in methylcellulose in the presence of DMSO, 10 µM LEN, 10 µM Lsx, 1 mM EGTA, or 2 µM ionomycin, and they were evaluated for colony formation after ~10 d. For knockdown of human CRBN, GPR68, CAPN1, and CAPN2, MDSL cells were transduced with lentivirus and sorted for GFP + CD34 + cells. For knockdown of human CAST, KG-1α and F36P cells were transduced with lentivirus and sorted for GFP + CD34 + cells. Kasumi and THP1 cells were transduced with lentivirus encoding shCAST. Transduced cells were plated in methylcellulose in the presence of DMSO, 10 µM LEN, or 10 µM Lsx, and were evaluated for colony formation after 10 d. For knockdown of human SAA1, IRF9, ribosomal RNA processing 1B (RRP1B), regulator of calcineurin 1 (RCAN1), calcium homeostasis endoplasmic reticulum protein (CHERP), epilepsy, progressive myoclonus type 2A, Lafora disease (laforin) (EPM2A), or RAR related orphan receptor B (RORB), MDSL cells were transduced with lentivirus (pLKO.1-Puro) and plated in methylcellulose that contained 2 µg/ml puromycin (61-385-RA; Fisher) and either DMSO or 10 µM LEN.
Cell death assay. Annexin V analysis was carried out as previously described 35 . Cultured cells were stained with Annexin V-APC (eBioscience; 88-8007-74) and 7AAD (eBioscience; 00-6993-50) according to the manufacturer's instructions. For MDSL, TF1, KG-1α, and F36P cells, the CD34 + compartment was gated for apoptosis analysis.
